Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September, 11, 2024 at 12:00 pm ET in New York, NY.
A webcast of the presentation will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904911170/en/
Contacts
Investor and Media Contact:
Gitanjali Jain
Senior Vice President, Investor Relations and External Affairs
Kezar Life Sciences, Inc.
gjain@kezarbio.com
